CLOUD MD SOFTWARE update...

originally published Monday, April 27, 2020

All Biotech & Medical Stocks

We made a quick almost 50% gain in CloudMD Software which we bought a week ago, selling it during the final minutes of trading this afternoon – if you weren’t fast enough don’t worry, because you may get an even better price in the early trade tomorrow morning. However, you should aim to get out as soon as possible because after today’s extremely heavy record-by-far volume, the chances are high that it will burn out very soon.

The reasons for taking profits are set out on the latest 5-month chart below. One reason isn’t shown, which is the quite heavy resistance above this level arising from trading above this level during the latter part of 2018 and the earlier part of 2019, that can be seen to advantage on a 2-year chart.


This stock remains in a bullmarket and we will be on the lookout for a chance to buy it back later after a correction or a healthy period of consolidation.

CloudMD website

CloudMD Software & Services Inc, DOC.CSX, DOCRF on OTC, closed at C$0.75, $0.516 on 27th April 20.


Posted at 5.50 pm EDT on 27th April 20.

The above represents the opinion and analysis of Mr Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment or securities advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market technical analyst, Clive Maund is not a Registered Investment Advisor or Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be construed as a recommendation or solicitation to buy and sell securities.